Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Prognostic factors and treatment of pediatric acute lymphoblastic leukemia.

Lee JW, Cho B.

Korean J Pediatr. 2017 May;60(5):129-137. doi: 10.3345/kjp.2017.60.5.129. Epub 2017 May 31. Review.

2.

Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia.

Shin S, Hwang IS, Kim J, Lee KA, Lee ST, Choi JR.

Ann Lab Med. 2017 Jul;37(4):331-335. doi: 10.3343/alm.2017.37.4.331.

3.

Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.

Campana D, Pui CH.

Blood. 2017 Apr 6;129(14):1913-1918. doi: 10.1182/blood-2016-12-725804. Epub 2017 Feb 6. Review. No abstract available.

PMID:
28167658
4.

Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia.

Karol SE, Larsen E, Cheng C, Cao X, Yang W, Ramsey LB, Fernandez CA, McCorkle JR, Paugh SW, Autry RJ, Lopez-Lopez E, Diouf B, Jeha S, Pui CH, Raetz EA, Winick NJ, Carroll WL, Hunger SP, Loh ML, Devidas M, Evans WE, Yang JJ, Relling MV.

Leukemia. 2017 Jun;31(6):1325-1332. doi: 10.1038/leu.2017.24. Epub 2017 Jan 18.

PMID:
28096535
5.

Role of B Cell Development Marker CD10 in Cancer Progression and Prognosis.

Mishra D, Singh S, Narayan G.

Mol Biol Int. 2016;2016:4328697. Epub 2016 Nov 14. Review.

6.

Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia.

Mayfield JR, Czuchlewski DR, Gale JM, Matlawska-Wasowska K, Vasef MA, Nickl C, Pickett G, Ness SA, Winter SS.

Pediatr Blood Cancer. 2017 May;64(5). doi: 10.1002/pbc.26328. Epub 2016 Nov 15.

PMID:
27860260
7.

Minimal Residual Disease Detection and Evolved IGH Clones Analysis in Acute B Lymphoblastic Leukemia Using IGH Deep Sequencing.

Wu J, Jia S, Wang C, Zhang W, Liu S, Zeng X, Mai H, Yuan X, Du Y, Wang X, Hong X, Li X, Wen F, Xu X, Pan J, Li C, Liu X.

Front Immunol. 2016 Oct 4;7:403. eCollection 2016.

8.

A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies.

Yang T, Lin Q, Ren J, Chen P, Yuan X, Luo X, Liu T, Zheng J, Zheng Z, Zheng X, Chen X, Zhang L, Zheng H, Chen Z, Hua X, Le S, Li J, Chen Z, Hu J.

Oncotarget. 2016 Nov 29;7(48):78773-78786. doi: 10.18632/oncotarget.12383.

9.

Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.

Pui CH, Pei D, Raimondi SC, Coustan-Smith E, Jeha S, Cheng C, Bowman WP, Sandlund JT, Ribeiro RC, Rubnitz JE, Inaba H, Gruber TA, Leung WH, Yang JJ, Downing JR, Evans WE, Relling MV, Campana D.

Leukemia. 2017 Feb;31(2):333-339. doi: 10.1038/leu.2016.234. Epub 2016 Aug 18.

10.

Role of peripheral blood minimum residual disease at day 8 of induction therapy in high-risk pediatric patients with acute lymphocytic leukemia.

Salina TD, Ferreira YA, Alves EB, Ferreira CM, De Paula EV, Mira MT, Passos Lda M.

Sci Rep. 2016 Aug 16;6:31179. doi: 10.1038/srep31179.

11.

Curcumin Veto the Effects of Osteopontin (OPN) Specific Inhibitor on Leukemic Stem Cell Colony Forming Potential via Promotion of OPN Overexpression.

Mohammadi S, Ghaffari SH, Shaiegan M, Nikogoftar Zarif M, Nikbakht M, Alimoghaddam K, Ghavamzadeh A.

Int J Hematol Oncol Stem Cell Res. 2016 Jul 1;10(3):120-9.

12.

Association of germline genetic variants in RFC, IL15 and VDR genes with minimal residual disease in pediatric B-cell precursor ALL.

Dawidowska M, Kosmalska M, Sędek Ł, Szczepankiewicz A, Twardoch M, Sonsala A, Szarzyńska-Zawadzka B, Derwich K, Lejman M, Pawelec K, Obitko-Płudowska A, Pawińska-Wąsikowska K, Kwiecińska K, Kołtan A, Dyla A, Grzeszczak W, Kowalczyk JR, Szczepański T, Ziętkiewicz E, Witt M.

Sci Rep. 2016 Jul 18;6:29427. doi: 10.1038/srep29427.

13.

A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1.

Rodriguez V, Kairalla J, Salzer WL, Raetz EA, Loh ML, Carroll AJ, Heerema NA, Wood BL, Borowitz MJ, Burke MJ, Asselin BL, Devidas M, Winick NJ, Carroll WL, Hunger SP, Dreyer ZE.

J Pediatr Hematol Oncol. 2016 Aug;38(6):409-17. doi: 10.1097/MPH.0000000000000589.

PMID:
27299599
14.

Eye on the B-ALL: B-cell receptor repertoires reveal persistence of numerous B-lymphoblastic leukemia subclones from diagnosis to relapse.

Bashford-Rogers RJ, Nicolaou KA, Bartram J, Goulden NJ, Loizou L, Koumas L, Chi J, Hubank M, Kellam P, Costeas PA, Vassiliou GS.

Leukemia. 2016 Dec;30(12):2312-2321. doi: 10.1038/leu.2016.142. Epub 2016 May 23.

15.

Minimal residual disease.

Campana D.

Leuk Suppl. 2012 Aug;1(Suppl 2):S3-4. doi: 10.1038/leusup.2012.5. Epub 2012 Aug 9.

16.

Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia.

Rocha JM, Xavier SG, de Lima Souza ME, Assumpção JG, Murao M, de Oliveira BM.

Mediterr J Hematol Infect Dis. 2016 Apr 10;8(1):e2016024. doi: 10.4084/MJHID.2016.024. eCollection 2016. Review.

17.

Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia.

Liu C, Yang W, Devidas M, Cheng C, Pei D, Smith C, Carroll WL, Raetz EA, Bowman WP, Larsen EC, Maloney KW, Martin PL, Mattano LA Jr, Winick NJ, Mardis ER, Fulton RS, Bhojwani D, Howard SC, Jeha S, Pui CH, Hunger SP, Evans WE, Loh ML, Relling MV.

J Clin Oncol. 2016 Jun 20;34(18):2133-40. doi: 10.1200/JCO.2015.64.5812. Epub 2016 Apr 25.

18.

Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232.

Larsen EC, Devidas M, Chen S, Salzer WL, Raetz EA, Loh ML, Mattano LA Jr, Cole C, Eicher A, Haugan M, Sorenson M, Heerema NA, Carroll AA, Gastier-Foster JM, Borowitz MJ, Wood BL, Willman CL, Winick NJ, Hunger SP, Carroll WL.

J Clin Oncol. 2016 Jul 10;34(20):2380-8. doi: 10.1200/JCO.2015.62.4544. Epub 2016 Apr 25.

PMID:
27114587
19.

Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: An Economic Analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2016 Mar 8;16(8):1-83. eCollection 2016. Review.

20.

Minimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: A Clinical Evidence Review.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2016 Mar 8;16(7):1-52. eCollection 2016. Review.

Supplemental Content

Support Center